RTP Mobile Logo
Submitted by web@researchtop... on Thu, 06/13/2019 - 17:04

 

Interview with Bradley J Monk, MD

Track 1: Guidelines for germline and somatic BRCA testing in ovarian cancer
Track 2: Incidence and potential impact of other clinically relevant genetic abnormalities on clinical decision-making in the front-line setting
Track 3: Patient selection for neoadjuvant systemic therapy in clinical practice
Track 4: Bevacizumab as a component of neoadjuvant systemic therapy for patients with ovarian cancer
Track 5: Clinical approach to patient selection for neoadjuvant chemotherapy; perspective on optimal schedule and dose of neoadjuvant regimen
Track 6: Importance of the extent of response to neoadjuvant chemotherapy in the timing of debulking surgery
Track 7: Therapeutic approach for patients with newly diagnosed ovarian cancer, germline BRCA mutations, bilateral pleural effusions and liver metastases
Track 8: Lingering controversies regarding the use of intraperitoneal chemotherapy for ovarian cancer
Track 9: GOG-0252: Design and results of a Phase III trial of intravenous or intraperitoneal chemotherapy, each in combination with bevacizumab, for advanced ovarian cancer
Track 10: Perspective on the recent FDA approval of bevacizumab in combination with carboplatin and paclitaxel followed by single-agent bevacizumab for Stage III or IV epithelial ovarian cancer after initial surgical resection
Track 11: Importance of disease stage and amount of residual disease in the decision to use bevacizumab as a component of primary therapy after debulking surgery
Track 12: Evaluating the optimal duration of maintenance bevacizumab
Track 13: Effect of bevacizumab on progression-free survival for patients with high-risk disease
Track 14: Risk of bevacizumab-associated gastrointestinal perforation; contraindications to bevacizumab
Track 15: Perspective on combining a PARP inhibitor with bevacizumab as maintenance therapy for patients with advanced platinum-sensitive ovarian cancer
Track 16: PAOLA-1: An ongoing Phase III trial of olaparib combined with bevacizumab as maintenance therapy for patients with advanced ovarian cancer after first-line platinum-based chemotherapy in combination with bevacizumab
Track 17: Practical approaches to mitigating carboplatin/paclitaxel-induced peripheral neuropathy
Track 18: Comparison of treatment-associated neurotoxicity with nab paclitaxel and solvent-based paclitaxel
Track 19: Clinical experience with bevacizumab for ovarian cancer; management of hypertension and proteinuria
Track 20: Activity and ongoing investigation of anti-angiogenic agents alone or in combination with PARP inhibitors for advanced ovarian cancer
Track 21: FDA breakthrough therapy designation for lenvatinib in combination with pembrolizumab for previously treated advanced microsatellite instability (MSI)-nonhigh/mismatch repair proficient endometrial cancer
Track 22: Rationale for the design of ongoing studies combining immune checkpoint inhibitors with anti-angiogenic agents and/or PARP inhibitors
Track 23: Modulation of gut microbiome to enhance response to anti-PD-1 immunotherapy; impact of antibiotics on response to treatment with immune checkpoint inhibitors

Interview with Professor Jonathan A Ledermann

Track 1: Biology and histopathologic subtypes of ovarian cancer
Track 2: Structure of gynecologic oncology clinical practice in the United Kingdom
Track 3: Approach to mutation testing for patients with newly diagnosed ovarian cancer
Track 4: Primary debulking surgery versus neoadjuvant systemic therapy in the up-front management of advanced ovarian cancer
Track 5: Value of neoadjuvant chemotherapy versus up-front debulking surgery followed by adjuvant chemotherapy
Track 6: Higher incidence of visceral metastases in patients with ovarian cancer and BRCA1/2 mutations
Track 7: Optimal timing of debulking surgery with (neo)adjuvant chemotherapy for newly diagnosed ovarian cancer
Track 8: Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery for advanced ovarian cancer; duration of maintenance therapy with bevacizumab
Track 9: ICON8: Results of a Phase III trial evaluating response to neoadjuvant weekly dose-dense chemotherapy as first-line therapy for epithelial ovarian cancer
Track 10: Influence of performance status and age on the choice of neoadjuvant versus adjuvant chemotherapy
Track 11: Activity and ongoing investigation of PARP inhibitors in combination with chemotherapy and/or bevacizumab and as maintenance therapy for patients with newly diagnosed ovarian cancer with and without germline BRCA mutations
Track 12: Consideration of bevacizumab as a component of (neo)adjuvant systemic therapy for patients with ovarian cancer
Track 13: Choosing between bevacizumab and olaparib after primary debulking surgery; importance of timely BRCA mutation analysis to aid in this decision
Track 14: Progression-free survival benefit with bevacizumab in combination with and after chemotherapy for patients with surgically debulked disease
Track 15: Incidence of gastrointestinal toxicities with up-front bevacizumab for ovarian cancer
Track 16: Approach to discontinuation of maintenance bevacizumab before surgery
Track 17: MSI/DNA mismatch repair testing in ovarian cancer
Track 18: PARP inhibitor-associated insomnia
Track 19: Case: A woman in her late 50s is diagnosed with Stage IV high-grade serous ovarian cancer with a germline BRCA1 mutation
Track 20: Counseling patients with ovarian cancer with germline BRCA mutations who did not receive PARP inhibition as a component of initial therapy about potential use of these agents in future treatment
Track 21: Impact of BRCA mutation status on patient prognosis and potential responsiveness to platinum-based chemotherapy
Track 22: Case: A woman in her early 70s with Stage IV high-grade serous ovarian cancer with a germline BRCA1 mutation receives olaparib on the Phase III SOLO-1 trial
Track 23: Case: A woman in her early 60s with suboptimally debulked Stage IV high-grade serous ovarian cancer receives adjuvant chemotherapy/bevacizumab followed by maintenance bevacizumab
Track 24: Biologic rationale for and ongoing evaluation of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors for newly diagnosed ovarian cancer
Track 25: Benefits and limitations of commercially available HRD (homologous recombination deficiency) testing platforms
 
FACULTY
 
Professor Jonathan A Ledermann
Professor of Medical Oncology
Clinical Director
University College London
Cancer Institute
Director
Cancer Research UK and
UCL Cancer Trials Centre
London, United Kingdom
 
Bradley J Monk, MD
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona
College of Medicine
Creighton University School of Medicine
St Joseph’s Hospital
Medical Director
US Oncology Research Network – Gynecologic Program
Phoenix, Arizona
 
MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida